Second Quarter 2023 Earnings

Full Year 2023 Guidance 9 (In millions, except per share and percentage data) Enzyme Products Revenue¹ ROCTAVIAN Revenue VOXZOGO Revenue Total Revenues Gross Margin % GAAP Diluted EPS Prior Guidance As of April 26, 2023 $1,700 $1,850 $50 - $150 $380 - $430 $2,375 - $2,500 77.5% -79% Current Guidance As of July 31, 2023 Unchanged Unchanged $400 - $440 Unchanged Unchanged Unchanged 35.5% -37.5% $165 - $215 $0.83 - $1.08 R&D % of Revenue 30% -32% SG&A % of Revenue 36% -38% GAAP Net Income $155 - $205 $0.78 - $1.03 Non-GAAP Net Income $360 - $410 Non-GAAP Diluted EPS2 $1.80 - $2.05 $1.85 - $2.10 1 Enzyme Products include ALDURAZYME®, VIMIZIMⓇ, NAGLAZYME®, BRINEURAⓇ, and PALYNZIQⓇ. 2 2023 GAAP and Non-GAAP Diluted EPS guidance assumes ~200 million shares. BIOMARIN $370 - $420

View entire presentation